N-oleoyl-dopamine (OLDA), a condensation product of oleic acid and dopamine (DA), is a bioactive lipid whose biological functions are not yet fully explored. The compound crosses the blood-brain barrier and might be considered as a carrier of DA into the brain. In this study we sought to determine whether OLDA would influence locomotor behavior and whether the central DA system would be involved in such influence. We addressed this issue by investigating horizontal locomotor activity in male Wistar rats after intraperitoneal administration of OLDA, 5-20 mg/kg, before and after pretreatment with haloperidol, a D z receptor antagonist. We found that OLDA caused a prompt stimulation of locomotor activity, with a bell-shaped dose-response. The maximum stimulatory effect was observed after 10 mg/kg of OLDA where the mean distance traveled by rats during a 2-hour test increased to 1213 ±196(SE) em from the 403 ±89 em in the vehicle-treated rats (P<0.05). This effect was dose-dependently antagonized by haloperidol (0.1-0.2 mg/kg). The results support the hypothesis that the OLDA-induced hyperlocomotion was mediated by the stimulation of DA systems. Using in vitro assays, we further demonstrated that OLDA is a stable compound that resists hydrolysis over a 2-hour period and thus the integral OLDA compound exerted DA-Iike effects. We conclude that OLDA is a potential brain modifier of motor behavior, the biological consequences of which remain to be explored.
brain. Thus, apart from interacting with TRPVI receptors, OLDA may produce central DA-like effects. Stimulation of dopaminergic activity is one mechanism that is involved in the induction and increase of rodents' locomotor behaviors (8) and in the formation of motor memories contributing to motor learning and skill acquisition (9) . In the present study we investigate the hypothesis that OLDA affects the expression of locomotor behavior, which may be linked to DA mediation. We addressed this issue by comparing locomotor activity in alert rats before and after systemic administration of OLDA. We found that OLDA increased appreciably horizontal locomotor activity in rats and that this effect was countered by haloperidol, a DA O 2 receptor antagonist, which strongly suggests the involvement of a DA pathway. In in vitro assays we further demonstrate that OLDA is a stable compound that resists hydrolysis and thus the integral OLDA compound exerted the DA-like effects.
MATERIALS AND METHODS

Animals
The experiments were approved by the Bioethics Committee as compliant with the Polish Law ofAugust 2 I, 1997 and were carried out in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Male Wistar rats weighing 250-270 g at the beginning of the experiment were used. The study comprised several experimental groups (see below). The rats were housed in standard plastic rodent cages (57x35x20 em; length, width, and height, respectively), 8 per cage, in a colony room maintained at 21 ±loC and 50% humidity under a 12 h light/dark cycle (lights on at 6: 00 a.m.). The animals had continuous access to tap water and rodent feed. The housing conditions were the same as those routinely used in behavioral studies (10) (11) .
Locomotor activity measurement
Locomotor activity was recorded individually for each animal in Opto-Varimex cages (Columbus Instruments, Columbus, OH) linked on-line to an IBM-PC. Each cage (43x44x25 em; length, width, and height, respectively) was surrounded with a 15xl5 array of photocell beams located 3 em from the floor surface as reported previously (10, 12) . Interruptions of the beams express horizontal locomotor activity defined as the distance traveled (in em). Rats were habituated to the experimental cage for two days (2 h/day) and for I h before testing; after the latter a control recording of locomotor activity was taken.
Then, the animals were taken out, injected with drugs and put back into the cage. The recording of locomotor activity was continued for a 2-hour test session and was analyzed using Auto-Track software (Columbus Instruments; Columbus, OH).
Experimental groups and compounds administered
The use of several control and test compounds necessitated a number of experimental groups to sort out the specificity of the OLDA effects. The following groups of animals (7-8 rats/group) were used: DMSO-treated, OLDA-treated (5, 10 and 20 mg/kg), Hp+DMSOtreated, haloperidol (0.1 mg/kg and 0.2 mg/kg)+DMSOtreated, Hp+OLDA-treated (10 mg/kg), haloperidol (0.1 mg/kg and 0.2 mglkg)+OLDA-treated (10 mg/kg). All compounds were injected intraperitoneally (ip) in a volume of I mIlkg. Haloperidol was dissolved in distilled water and OLDA in DMSO. Ready-to-use solution of DMSO (Sigma-Aldrich, Poznan, Poland) of minimum purity of 99.5% was used for control injections and as a solvent for OLDA. Stock solutions containing a given dose of OLDA per I ml of DMSO were made ex tempore as required. Haloperidol was administered 60 min before OLDA or DMSO. Measurements of locomotor activity began immediately after OLDA or DMSO. Each animal was tested only once.
Haloperidol (from 5 mg/ml original ampoules) was purchased from Polfa (Warsaw, Poland) and OLDA was generously provided by Prof. Z. Czarnocki of the Faculty of Chemistry of Warsaw University in Warsaw, Poland, where it was synthesized. The compound's purity was in a range of 96-98%, which was assessed using I HNMR spectroscopy (Varian Unity 500 NMR Spectrometer; Palo Alto, CA) and additionally confirmed with thin-Iayeredchromatography.
Stability ofOLDA
The nature of the OLDA compound was studied by assessing its propensity for hydrolysis in both the Krebs solution and the membrane and cytosolic fractions of brain homogenates.
Inorganic Krebs medium
The Krebs solution contained 118.0 mM NaCl, 6.0 mM KCI, 0.6 mM NaHl04, 2.5 mM CaCI 2 , 1.2 mM MgS0 4, 25.0 mM NaHC0 3 ; pH 7.4 adjusted with carbogen, 5% CO 2 in O 2 , Six micromoles of OLDA were suspended in 2-3 drops of Tween 80 and the composition, in tum, in 6 ml of the Krebs solution to a final concentration of 1.0 mM. The solution mixture was continually stirred at 37°C throughout the analysis time of 2 h. OLDA was omitted in the control solution. Half milliliter samples of both OLDA-Ioaded and control aqueous solutions were taken at baseline and then every 30 min up to 2 h. Both OLDA and control solutions were centrifuged at 1200 x g for 20 min at 4°C. OLDA was extracted four times in a row with 0.25 ml of chloroform. The organic phases were pooled and evaporated under nitrogen. The residue was dissolved in 200 ul of chloroform and analyzed spectrophotometrically with a double-beam computercontrolled ultraviolet/visible spectrophotometer (Cintra lOe UVIVIS and Spectral 1.70 software, GBC Scientific Equipment Pty, Victoria, Australia).
Brain homogenates
Three male Wistar rats anesthetized with a-chloralose and urethane (35 and 800 mg/kg, ip, respectively) were used in this part of the study. The rats were euthanized by perfusion with ice-cold 0.9% NaCl through the left of the heart. Brains were enucleated and the brain tissue membrane fraction was isolated according to the method of Xu et a1. (13) . Brain tissue was homogenized ex tempore in a membrane isolation buffer (1:5 w/v) consisting of 2.5 mM MgC1 2 , 1.0 mM NaHC0 3 , 2.0 mM Tris-HCl; 3.0 mM EDTA, 100~M benzamidine, and 100~M PMSF, pH 7.4; all obtained from Sigma-Aldrich (Poznan, Poland). Homogenates were centrifuged at 2000 x g for 10 min at 4°C; sediments were then discarded and the supernatants were re-centrifuged at 40000 x g for 18 min at 10°C in an L7 Ultracentrifuge (Beckman Instruments; Palo Alto, CA). The pellets obtained from the latter centrifugation, representing the membrane fraction, were washed twice with the isolation buffer, whereas supernatants were collected as a cytosolic fraction. Both membrane and cytosolic fractions were suspended in the isolation buffer, frozen to -80°C and kept for a maximum of 4 days until further analysis. On the day of analysis, membrane and cytosolic fractions were each diluted to a volume of 12 ml in the Krebs and isolation buffers, respectively. Half of the volume was taken as a control and 6 umol of OLDA suspended in 2-3 drops of Tween 80 was added to the other half. Next, 500 ul samples were taken from both stock solutions every 30 min. A hundred microliters of 8% trichloroacetic acid (Sigma-Aldrich; Poznan, Poland) were added to each sample and the sedimented protein pellets were centrifuged off at 2000 x g for 4 min at 4°C. Supernatants were subjected to the extraction procedure, and then 200 ul samples were taken and analyzed spectrophotometrically; all in the manner described above for the inorganic Krebs solution. Additionally, spectrophotometric measurements of DA alone were performed in the aqueous solution. No trace of DA spectra was detected in these measurements (data not shown).
Thin layer chromatography (TLC)
The integrity of the OLDA compound In brain homogenates was additionally confirmed in two rat brains with the use of TLC. Twenty microliters of spectrophotometered samples of both membrane and cytosolic fractions and OLDA standard (dissolved in chloroform, 100 ug/ml) were applied on TLC silica gel 60 A plates Merck KGaA (Darmstadt, Germany), using chlorofonn:methanol (95:5, v/v) as solvents. The plates were developed with iodine vapor and the resolved spots were immediately photocopied.
Statistical analysis
Data were expressed as the arithmetic mean (±SE) of total locomotor activity counts for the 2-hour observation period. One-way analysis of variance (ANOVA) followed by the Dunnett post hoc test was used to evaluate differences in the OLDA treatment group. Two-way ANOVA followed by the Newman-Keul post hoc test was used to evaluate differences in the haloperidol + OLDA treatment combination. P<0.05 was taken as significant. Fig. 1 shows a series of representative UV spectra recorded in individual brain membrane (Panel A) and cytosolic (Panel B) fractions, which were obtained from untreated, control brain homogenates (curve 'H') and those at 1, 30, and 60 min after the addition of OLDA. For the control samples the absorbance tended to zero in the investigated spectral range. In contrast, the intensity of absorption was about equally high for the OLDA-loaded samples in both membrane and cytosolic fractions. The peak absorbance was invariably at 281.9 nm. The results of UV spectrophotometric determinations were similar in the OLDA-loaded inorganic Krebs solution with the peak absorbance at the same wavelength (not shown). There was no meaningful change in the shape of the spectra over time in either brain fractions or Krebs medium, which reveals a structural integrity of the compound.
RESULTS
Nature ofOLDA
The integrity ofthe OLDAcompound was verified by the results. of TLC screening performed in brain extracts. The OLDA bands appeared at the level of the OLDA standard. In both membrane and cytosolic fractions, the R f factors of the spots corresponding to the OLDA-loaded brain samples were nearly identical to those of the OLDA standard (data not shown). In the cytosolic fraction, R, amounted to 0.21 and 0.22 after 1 hand 2 h, respectively, as compared with 0.22 for the OLDA standard. The respective R, values in the membrane fraction were 0.23 and 0.25 in biological samples and 0.25 for the standard. Fig. 2 shows the effects of OLDA treatment in the doses of 5, 10, and 20 mg/kg on locomotor activity expressed as a distance traveled in consecutive 15 min intervals up to 2 h of the test session (Panel A) and the summed distance covered during the whole session (Panel B). All three doses of OLDA significantly increased locomotor activity compared with the control DMSO-treated group (F 3 . 27=8.05, P<O.O 1). The increase in locomotor activity became evident 15 min after injection, thereafter gradually abating toward the baseline level at 45 min. The effect was the strongest and longest lasting for the medium dose of OLDA (10 mg/kg). The stimulatory effect of OLDA, particularly in a dose of 10 mg/kg, on locomotor activity was also apparent when the summary distances covered during the session time were collated (Fig. 2, Panel B) . Overall, the mean distance traveled by the rats during 2 h increased from 403 ±89 em in the vehicle-treated to 1213 ± 196 em in the OLDA (10 mg/kg)-treated rats (P<0.05). For further combination experiments (see below), 10 mg/kg of OLDA was employed as it stimulated locomotor activity in a more dedicated way.
Effects ofOLDA on locomotor activity
Effects of haloperidol on the OLDA-induced locomotor activation
The effect ofhaloperidol, aD2receptor antagonist, on the OLDA-induced locomotor activation is shown in Fig. 3 . Haloperidol, either 0.1 mg/kg or 0.2 mg/kg, administered prior to the vehicle did not significantly alter basal locomotor activity, although the higher dose tended to suppress the locomotor activity and the effects of the two doses differed from each other (F 2.42=5.04, P<O.Ol). OLDA, in a dose of 10 mg/kg, significantly stimulated locomotor activity; the mean distance traveled by rats in 2 h increased from 260 ±31 em at baseline with DMSO alone to 623 ±117 em with OLDA (Fl. s=12.54, P<O.OOl). Pre-treatment with haloperidol dose-dependently restrained the locomotor hyperactivity induced by OLDA. After the 0.2 mg/kg dose of haloperidol the stimulatory effect of OLDA was no longer present; the activity counts amounted to 188 ±32 em, which was not significantly different from the DMSOalone baseline.
DISCUSSION
The novel finding of this study is that OLDA induced locomotor hyperactivity in rats. Furthermore, we showed that the above effect was counteracted by pre-treatment with haloperidol, aDA D 2 receptor antagonist, which suggests a dopaminergic pathway being involved in the effect. N-oleoyl-dopamine, a synthetic amide of oleic acid and dopamine, is a lipophilic compound that raises interest as a possible brain function modifier due to its capability of carrying DA into the brain. However, neither the interaction of OLDA with the components of the dopaminergic system nor biological consequences of such interaction have yet been explored.
The temporal pattern of locomotor activation observed in this study is commensurate with the ability of radiolabeled OLDA to readily cross the blood-brain barrier after systemic administration and to distribute in the striatum and motor and sensory cortices (4), the areas rich in DA known to regulate the motor function (14) . Locomotor-activating effects of OLDA resemble those of direct DA receptor agonists that stimulate postsynaptic DA receptors, as well as indirect DA agonists (e.g. amphetamine or cocaine) that increase DA efflux (14) . In fact, we observed that the dose-response curve for OLDA was bell-shaped, as are those reported for a number of direct and indirect dopaminergic agents (15) (16) . Moreover, it is well documented that hyperactivity induced by both direct and indirect DA agonists is blocked by haloperidol (17) (18) (19) (20) , a preferential D 2 receptor antagonist (21) (22) . In the present study, haloperidol prevented, in a dose-dependent manner, the OLDA-induced hyperlocomotion, not altering basal locomotor activity in well-habituated animals. This finding makes the involvement of postsynaptic D 2 receptors in OLDA's facilitation of locomotor activity an explicative proposition.
Considering DA function in connection with behavioral responses to OLDA, several issues should be tackled. OLDA could interact with DA receptors as an integral compound or DA could dissociate off and then interact with its receptors. Our previous 
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.... work showed that OLDA does not disintegrate in brain tissue within 15 min after systemic administration (4), the time of peak locomotor stimulation observed in the present study. We now expand on that earlier work by showing that OLDA is a stable compound that resists hydrolysis for up to two hours. Qualitative spectrophotometric and TLC screening, verified by OLDA standards, failed to detect signs of its hydrolysis in both inorganic Krebs medium and brain homogenates. These data are in accordance with those of others who showed that dopamides, in general, resist hydrolysis by fatty acid amide hydrolase (FAAH), the enzymatic system abundantly present in rat brain tissue, on account of their being, in fact, competitive inhibitors of the enzyme (23) . OLDA, in particular, is a poor substrate for FAAH (5) and might therefore interact with DA receptors as an integral compound. The interaction of OLDA with DA receptors has not yet been directly explored. Another member of the dopamide family, N-arachidonoyl-dopamine, in in vitro assays failed to displace D 1 or Dzhigh affinity ligands from rat brain membranes (23) . N-arachidonoyl-dopamine is, however, a cannabimimetic with different behavioral effects in vivo than OLDA and, in contrast to OLDA, with no appreciable affinity to TRPV 1 receptors (5) . Thus, the issue of OLDA interaction with DA receptors cannot be readily resolved by analogy with other dopamides. A stimulatory effect on locomotor activity of OLDA mediated by its interaction with TRPVl receptors seems unlikely, for capsaicin and arvanil, TRPV 1 agonists, suppress, rather than enhance, basal locomotor activity in mice and the effect of capsaicin is blocked by the TRPVl receptor antagonist capsazepine (24) .
There are other possible ways in which OLDA could be involved in the DA pathway. OLDA could serve the purpose of enhancing the behavioral consequences of DA receptor activation or act indirectly to intensify the effects of other bioactive compounds involved in motor control. Finally, OLDA could increase release of central DA or the activity of tyrosine hydroxylase, the rate-limiting enzyme for DA synthesis. However, it should be raised that OLDA in the same dose as that which produced locomotor activation (10 mg/kg) did not substitute for the indirect DA agonist cocaine in a drug discrimination paradigm, as only 10% of cocaine-appropriate responding was observed (Filip and Przegalinski, unpublished results). Since several direct and indirect DA receptor agonists produce a full (>80% of cocaine-appropriate responding) substitution for cocaine (25) (26) (27) , behavioral actions of OLDA related to DA function should be taken with limitation. Alternative study designs would be required to establish the exact determinants of OLDA-DA interaction.
There appear to be more than just DA-linked explanations that could partly account for the attenuation by haloperidol of the OLDA-mediated stimulation of locomotor activity. Haloperidol has high affinity for sigma receptor sites. It competitively displaces ligands for cerebral sigma receptors in conscious monkey (28) and antagonizes sigma receptors in in vitro assays (29) . Although the function of sigma receptors is largely unknown, they are involved in the regulation of locomotion and mediate retardation of motor behavior by haloperidol (30) . Indeed, haloperidol alone, in the higher dose of 0.2 mg/kg used in the present study, exhibited some suppressive effect on motor activity, which could be related to sigma receptors. Pre-treatment with haloperidol also kept in check the OLDA-induced hyperlocomotion, which would be in line with the assumption that the stimulatory effect ofOLDAmight have been due to the activation of sigma receptors. However, the extent to which sigma receptors could be involved in the haloperidol-mediated attenuation of the OLDA-induced hyperlocomotion remains open to conjecture.
We conclude that enhancement of locomotor activity by OLDA, as demonstrated in this study, is a hitherto unrecognized biological action of the dopamide. Our findings suggest that further investigations are warranted to establish the role of OLDA in the regulation of motor behaviors.
